Target intelligence / Profile preview

Cytochrome P450 3A25 (CYP3A25)

Target
CYP3A25
Molecular classification
Enzyme, Oxidoreductase
01

Overview

Cytochrome P450 3A25 is a member of the cytochrome P450 superfamily of enzymes, which catalyze the oxidation of xenobiotics, steroids, and lipids through monooxygenase reactions using a heme-thiolate structure[1][2][4]. While cytochrome P450 enzymes are critical for drug metabolism (notably human CYP3A4 and CYP3A5[2]), CYP3A25 itself is primarily characterized in rodents and serves as a counterpart to the human CYP3A subfamily. It is involved in the hepatic metabolism of various endogenous and exogenous compounds. The cytochrome P450 family as a whole is widely recognized for its key role in drug metabolism, pharmacokinetic variability, and potential drug–drug interactions[2][4]. CYP enzymes reside mainly in the liver and intestines, where they help clear potentially toxic substances and drugs from the body[1][2]. CYP3A25 is the rodent ortholog of the human CYP3A family; in humans, the most prominent enzymes are CYP3A4 and CYP3A5[2][4]. CYP3A25 is not a human protein, but the structured classification and biochemical roles largely parallel those of the characterized human CYP3A subtypes. This is relevant for translational and comparative studies, especially for preclinical drug metabolism. If you require information specifically about human drug targets, refer to CYP3A4 or CYP3A5 instead[2][4]. "Cytochrome P450 3A25" is a valid canonical name for this specific enzyme in rodents. Standard abbreviation is CYP3A25. It is a member of the enzyme superfamily and is considered a drug-metabolizing target, mainly in preclinical (non-human) studies[1][2][4]. It does not have broadly accepted or clinically significant roles in human disease or drug interactions, but its human equivalents (CYP3A4/5) are extremely important in clinical pharmacology[2]. No direct biomarkers or clinically relevant safety concerns are unique to CYP3A25; general drug–drug interaction principles apply to cytochrome P450 enzymes[2][4].

Other names
CYP3A25Cytochrome P450 family 3 subfamily A member 25
02

Mechanism of action

Monooxygenase activity (adds an oxygen atom in substrate metabolism); Oxidation of endogenous and exogenous compounds

03

Biological functions

Xenobiotic metabolismDrug metabolismSteroid and lipid oxidation
04

Disease associations

Other (primarily implicated in drug metabolism and disposition, not directly in disease causation in humans)
05

Safety considerations

Potential for pharmacokinetic drug–drug interactions if expressed in species relevant to preclinical models

Beyond the preview

Go deeper on Cytochrome P450 3A25 (CYP3A25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 3A25 (CYP3A25).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call